Sugi Predict

Sugi Predict / Compounds / SCHEMBL3157164

SCHEMBL3157164

SCHEMBL3157164

COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCNCC2)cc1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 1/20 0.50
▸ PDGFRB P09619 2/20 0.43
▸ FGFR1 P11362 2/20 0.43
▸ PDGFRA P16234 2/20 0.43
▸ FLT1 P17948 2/20 0.43
▸ FGFR2 P21802 2/20 0.43
▸ FGFR4 P22455 2/20 0.43
▸ FGFR3 P22607 2/20 0.43
▸ FLT4 P35916 2/20 0.43
▸ KDR P35968 2/20 0.43
▸ ABL1 P00519 1/20 0.43
▸ NTRK1 P04629 1/20 0.43
▸ CSF1R P07333 1/20 0.43
▸ RET P07949 1/20 0.43
▸ KIT P10721 1/20 0.43
▸ NTRK3 Q16288 1/20 0.43
▸ CHEK1 O14757 1/20 0.42
▸ PRKAB2 O43741 1/20 0.42
▸ NUAK1 O60285 1/20 0.42
▸ MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3157176 1.00 AAK1 (0.50) AAK1PDGFRBFGFR1PDGFRAFLT1
SCHEMBL20807141 0.95 AAK1 (0.54) AAK1PDGFRBFGFR1PDGFRAFLT1
SCHEMBL2573197 0.94 AAK1 (0.44) AAK1PDGFRBFGFR1PDGFRAFLT1
SCHEMBL2573195 0.94 AAK1 (0.44) AAK1PDGFRBFGFR1PDGFRAFLT1
SCHEMBL2573136 0.94 AAK1 (0.51) AAK1PDGFRBFGFR1PDGFRAFLT1
SCHEMBL2573133 0.94 AAK1 (0.51) AAK1PDGFRBFGFR1PDGFRAFLT1
SCHEMBL2566302 0.93 AAK1 (0.51) AAK1PDGFRBFGFR1PDGFRAFLT1
SCHEMBL2566309 0.93 AAK1 (0.51) AAK1PDGFRBFGFR1PDGFRAFLT1
SCHEMBL2570069 0.92 AAK1 (0.44) AAK1PDGFRBFGFR1PDGFRAFLT1
SCHEMBL2570066 0.92 AAK1 (0.44) AAK1PDGFRBFGFR1PDGFRAFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200390909-A1 DRUG FRAGMENT IMAGING AGENT CONJUGATES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2020-12-17 — — US disclosed
WO-2017077551-A2 AN AMORPHOUS NINTEDANIB ESYLATE AND SOLID DISPERSION THEREOF MYLAN LABORATORIES LIMITED (IN) 2017-05-11 — — WO disclosed
EP-2157081-A1 Indolinones substituted in six locations, their manufacture and their application as medicine Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2010-02-24 — — EP disclosed
US-6762180-B1 Substituted indolines which inhibit receptor tyrosine kinases BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-07-13 — — US disclosed
EP-1224170-A1 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT Boehringer Ingelheim Pharma KG (DE) 2002-07-24 — — EP disclosed
WO-2001027081-A1 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390909-A1 DRUG FRAGMENT IMAGING AGENT CONJUGATES FUCA1, SI, FOLH1 AAK1 4402/4885PDGFRB 2129/4885FGFR1 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.